Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
J Infect Dis. 2012 Jun 15;205(12):1806-10. doi: 10.1093/infdis/jis285. Epub 2012 Apr 5.
The Step study of a recombinant adenovirus serotype 5 (Ad5)-based human immunodeficiency virus type 1 (HIV-1) vaccine revealed an increased risk of HIV-1 acquisition in vaccinees who were Ad5 seropositive at baseline. We therefore investigated whether preexisting Ad seropositivity to 7 different Ad serotypes was associated with increased risk of HIV-1 infection in 3 HIV-1 vaccine efficacy trials. In a case-control study involving 1570 adults enrolled in the VAX003 and VAX004 trials of a recombinant protein subunit HIV-1 vaccine and in the Step study, we observed that preexisting seropositivity to multiple Ad serotypes was not intrinsically associated with increased risk of HIV-1 acquisition.
一项基于重组腺病毒血清型 5 (Ad5) 的人免疫缺陷病毒 1 型 (HIV-1) 疫苗的 Step 研究表明，在基线时 Ad5 血清阳性的疫苗接种者中，HIV-1 感染的风险增加。因此，我们研究了 7 种不同的 Ad 血清型的预先存在的 Ad 血清阳性是否与 3 项 HIV-1 疫苗功效试验中的 HIV-1 感染风险增加有关。在一项涉及 1570 名成年人的病例对照研究中，这些成年人参加了重组蛋白亚单位 HIV-1 疫苗的 VAX003 和 VAX004 试验以及 Step 研究，我们观察到，对多种 Ad 血清型的预先存在的血清阳性与 HIV-1 获得的风险增加没有内在关联。
